J&J will resume rollout of the COVID-19 vaccine in Europe

Johnson & Johnson will resume rollout of the COVID-19 vaccine in Europe, the company announced Tuesday, with added packaging labels warning of a rare risk of blood clots.

The announcement came after the European health regulator, the European Medicines Agency, said the benefits of the vaccine outweigh the risk of the rare, potentially fatal side effect.

The launch of J & J’s vaccine in Europe was suspended after US regulators stopped using the company’s injection last week after it was reported that six women had contracted blood clots.

“It is an extremely rare event. We hope by raising awareness and providing clear diagnostic and therapeutic guidelines that we can restore confidence in our vaccine, ”J&J Chief Scientific Officer Paul Stoffels said in a conference call Tuesday.

Nearly 8 million people in the US have received the J&J vaccine.

The Centers for Disease Control and Prevention and the Food and Drug Administration are investigating the rare blood clots reported in people who received the injection.

With pole wires

.Source